科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02171 科济药业-B

已收盘 04-14 16:08:20

20.900

+2.100

+11.17%

最高21.280	最低18.750	成交量948.31万
今开18.990	昨收18.800	日振幅13.46%
总市值119.13亿	流通市值119.13亿	总股本5.70亿
成交额1.94亿	换手率1.66%	流通股本5.70亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02171","market":"HK","secType":"STK","nameCN":"科济药业-B","latestPrice":20.9,"timestamp":1776154100003,"preClose":18.8,"halted":0,"volume":9483059,"delay":0,"changeRate":0.11170212765957435,"floatShares":570000000,"shares":570000000,"eps":-0.2038404076145711,"marketStatus":"已收盘","change":2.1,"latestTime":"04-14 16:08:20","open":18.99,"high":21.28,"low":18.75,"amount":194272933,"amplitude":0.134574,"askPrice":20.96,"askSize":9500,"bidPrice":20.9,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":-0.2038404076145711,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776216600000},"marketStatusCode":5,"adr":0,"listingDate":1623945600000,"exchange":"SEHK","adjPreClose":18.8,"openAndCloseTimeList":[[1776130200000,1776139200000],[1776142800000,1776153600000]],"volumeRatio":2.990086,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02171/tweets","defaultTab":"tweets","newsList":[{"id":"1136591998","title":"科济药业-B2025年收入增至1.26亿元，CAR-T核心管线推动亏损显著收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1136591998","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136591998?lang=zh_cn&edition=full","pubTime":"2026-04-10 21:09","pubTimestamp":1775826551,"startTime":"0","endTime":"0","summary":"科济药业-B在截至2025年12月31日止年度实现收入约1.26亿元人民币，主要来自自体BCMA CAR-T细胞产品赛他泽的商业化销量增长。整体而言，科济药业-B在2025年度通过加强CAR-T产品商业化和高效管控，使收入明显增长、亏损幅度显著收窄，并在多靶点管线与通用型CAR-T平台上取得临床进展，彰显了细胞免疫疗法在血液和实体肿瘤领域的持续潜力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162990917","title":"科济药业-B更新3月股份变动月报表，股本增至578,170,999股","url":"https://stock-news.laohu8.com/highlight/detail?id=1162990917","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162990917?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:50","pubTimestamp":1775731853,"startTime":"0","endTime":"0","summary":"2026年4月9日，科济药业控股有限公司发布截至2026年3月31日的股份变动月报表。公告显示，公司法定股本数额维持在50,000美元，未发生增减变动。公司已发行股份由上月末的570,312,499股增加至570,352,999股，库存股份维持7,818,000股不变，当月合计新增40,500股，期末股份总数增至578,170,999股。新增部分主要来自首次公开发售后购股权计划的行使及2019年股权激励计划。截至月末，该计划所对应尚可行使或转让的股份总数为18,664,415股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618604733","title":"港股异动 | 科济药业-B(02171)再涨超12% 全年收入同比增超2倍 昨日起正式进入港股通名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2618604733","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618604733?lang=zh_cn&edition=full","pubTime":"2026-03-10 10:20","pubTimestamp":1773109241,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B再涨超12%，截至发稿，涨10.78%，报15.42港元，成交额1.27亿港元。消息面上，3月6日，科济药业发布年度业绩，收益1.26亿元人民币，同比增长218.7%；母公司拥有人应占亏损9786.1万元，同比收窄87.7%。值得注意的是，3月9日，科济药业正式获纳入港股通名单。本次纳入体现了市场对公司核心CAR-T业务发展潜力、经营规范性及股份流动性的认可，符合公司长期发展战略及全体股东的根本利益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411985.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02171","VXUS","BK1587","BK1574","BK1161","BK4588","BK4585","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156391493","title":"异动解读 | 获纳入港股通及业绩改善，科济药业-B盘中大涨5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156391493","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156391493?lang=zh_cn&edition=full","pubTime":"2026-03-10 09:36","pubTimestamp":1773106618,"startTime":"0","endTime":"0","summary":"科济药业-B今日盘中大幅上涨5.32%，引起了市场的广泛关注。消息面上，科济药业近期获重新纳入港股通标的，此举预计将吸引更多内地投资者，提升股票的流动性与市场关注度。同时，公司披露的2025年年报显示业绩显著改善，亏损额大幅收窄，增强了投资者信心。具体而言，公司的BCMA CAR-T产品泽沃基奥仑赛注射液在2025年实现销售额1.26亿元，并通过与华东医药的合作有效控制了销售成本。此外，科济药业拥有国内CAR-T领域最丰富的在研管线之一，包括接近上市的CLDN18.2 CAR-T及多款处于临床早期的通用型CAR-T产品，展现了强大的长期研发潜力。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618627333","title":"科济药业-B(02171.HK)授出426.7万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2618627333","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618627333?lang=zh_cn&edition=full","pubTime":"2026-03-09 22:37","pubTimestamp":1773067022,"startTime":"0","endTime":"0","summary":"格隆汇3月9日丨科济药业-B(02171.HK)宣布，于2026年3月9日，公司根据首次公开发售后购股权计划的条款向181名购股权承授人授出426.7万份购股权，惟须待购股权承授人接纳后方可作实。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260309/32055246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","02171","BK1587","BK1161","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618603965","title":"科济药业2025：亏损收窄87%，实体瘤CAR-T冲刺上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2618603965","media":"药智网","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618603965?lang=zh_cn&edition=full","pubTime":"2026-03-09 15:19","pubTimestamp":1773040781,"startTime":"0","endTime":"0","summary":"2025年，科济药业实现收益约1.26亿元，这一增长主要来源于其核心商业化产品赛恺泽的销售。2025年，科济药业净亏损收窄至约1.03亿元，较2024年的7.98亿元大幅减少约6.95亿元，同比收窄87.09%。现金流方面，截至2025年12月31日，公司现金及现金等价物约为11.23亿元。赛恺泽作为全人源BCMA靶向自体CAR-T细胞产品，2025年商业化进程全面加速。研发管线方面，科济药业2025年取得多项里程碑式进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030915325297aae146&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030915325297aae146&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","BK1585","02171","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618618185","title":"科济药业-B绩后大涨超32% 年度股东应占亏损同比收窄87.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618618185","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618618185?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:37","pubTimestamp":1773020220,"startTime":"0","endTime":"0","summary":"　　科济药业-B绩后大涨逾32%，截至发稿，股价上涨32.48%，现报14.40港元，成交额4770.84万港元。　　3月6日，科济药业-B发布截至2025年12月31日止年度业绩，收益1.26亿元，同比增长218.7%；母公司拥有人应占亏损9786.1万元，同比收窄87.7%；每股基本亏损0.18元。截至2025年12月31日止年度，集团的收益主要来自赛恺泽 ，其中赛恺泽的主要收益乃以出厂价格而非终端市场价进行计算的。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-03-09/doc-inhqizzp6892836.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","BK1587","BK1585","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123441748","title":"异动解读 | 科济药业-B纳入港股通，盘中大涨15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123441748","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123441748?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:31","pubTimestamp":1773019900,"startTime":"0","endTime":"0","summary":"科济药业-B(02171)今日盘中大涨15%，引起了市场的广泛关注。消息面上，公司股票被纳入沪港通及深港通南向交易的合资格股票名单（港股通），自今日起正式生效。此次纳入体现了市场对公司核心CAR-T业务发展潜力、经营规范性及股份流动性的认可，预计将吸引更多内地投资者，显著提升市场关注度和流动性。纳入港股通后，符合条件的中国内地投资者可通过上海证券交易所及深圳证券交易所港股通交易系统，直接买卖公司在香港联合交易所有限公司上市的股份，这为公司资本市场发展注入了强劲动力。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618058692","title":"科济药业-B(02171)纳入南向港股通证券名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2618058692","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618058692?lang=zh_cn&edition=full","pubTime":"2026-03-09 08:19","pubTimestamp":1773015549,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B 发布公告，根据发布于2026年3月6日《关于沪港通下港股通标的调整的通知》，及发布于2026年3月6日《关于深港通下港股通标的证券名单调整的公告》，公司发行并于香港联合交易所有限公司上市的股份纳入沪港通及深港通南向交易的合资格股票名单中，本次调整自2026年3月9日起正式生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1585","BK1161","BK4585","VXUS","02171","BK1574","161027","BK1587","VT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136865495","title":"科济药业-B预期2026年末现金及等价物不低于10亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1136865495","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136865495?lang=zh_cn&edition=full","pubTime":"2026-03-06 20:10","pubTimestamp":1772799016,"startTime":"0","endTime":"0","summary":"科济药业-B（股票代码：02171）近日披露，公司预计至2026年12月31日，其现金及现金等价物余额将维持在至少人民币10亿元的水平。这一财务预期反映了公司在资金管理方面的稳健策略，同时也为其未来在细胞治疗领域的研发投入和业务拓展提供了坚实的财务支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171","BK1585","BK1574","BK1587","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617687533","title":"科济药业-B(02171)发布2025年度业绩，股东应占亏损9786.1万元，同比收窄87.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617687533","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617687533?lang=zh_cn&edition=full","pubTime":"2026-03-06 20:06","pubTimestamp":1772798807,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B(02171)发布截至2025年12月31日止年度业绩，收益1.26亿元(人民币，下同)，同比增长218.7%;母公司拥有人应占亏损9786.1万元，同比收窄87.7%;每股基本亏损0.18元。截至2025年12月31日止年度，集团的收益主要来自赛恺泽® (自体BCMA CAR-T细胞产品)，其中赛恺泽®的主要收益乃以出厂价格而非终端市场价进行计算的。集团的收益于完成产品的出厂交付后确认。由于CAR-T生产存在必需的时间周期，从华东医药获得的订单数量与出厂交付的数量存在差异。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02171","BK1161","BK1587","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146356535","title":"科济药业-B（02171）更新2026年2月股份变动月报，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1146356535","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146356535?lang=zh_cn&edition=full","pubTime":"2026-03-05 18:35","pubTimestamp":1772706956,"startTime":"0","endTime":"0","summary":"科济药业控股有限公司于2026年3月5日发布的2026年2月股份变动月报显示，公司在本报告期内无新增股份发行或注销，整体股本结构维持不变。公司公告披露，截至2026年2月28日，法定注册股本为2,000亿股普通股，每股面值0.00000025美元，总额5万美元，与上月持平。根据公告，2025年10月曾在市场回购的455,000股普通股尚未完成注销。公告同时确认，公司遵守香港联交所《上市规则》及相关法律规定。本次报告由执行董事李宗海签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616762809","title":"港股异动 | 科济药业-B(02171)再跌超8% TCE优异数据引发市场对自体CAR-T前景担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=2616762809","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616762809?lang=zh_cn&edition=full","pubTime":"2026-03-02 11:31","pubTimestamp":1772422318,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B再跌超8%，截至发稿，跌8.06%，报13港元，成交额1892.91万港元。该行指出，自体CAR-T凭借优异的疗效具备极大的吸引力，2025年全球销售额已接近60亿美元。近期TCE优异的数据引起市场对自体CAR-T前景的担忧，主要因为疗效接近的情况下自体CAR-T复杂的制备和使用过程，以及高昂的成本带来的价格劣势格外突出。in vivo CAR-T是解决以上问题极具潜力的方向。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408846.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4230","BK1585","VT","BK1587","BK1161","BK4588","VXUS","02171","CAR","BK4585","BK1574","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614407861","title":"科济药业-B02月27日遭主力抛售25.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614407861","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614407861?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:15","pubTimestamp":1772180147,"startTime":"0","endTime":"0","summary":"02月27日, 科济药业-B股价跌1.60%，报收14.14元，成交金额2982.6万元，换手率0.38%，振幅8.42%，量比1.20。科济药业-B今日主力资金净流出25.0万元，上一交易日主力净流出113.7万元。该股近5个交易日下跌7.17%，主力资金累计净流入189.4万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入155.5万元，其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227161924a4cefd4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227161924a4cefd4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1585","BK1574","02171","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614080669","title":"每日卖空追踪 | 科济药业-B 02月25日卖空量成交7.05万股，卖空比例为5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614080669","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614080669?lang=zh_cn&edition=full","pubTime":"2026-02-25 16:30","pubTimestamp":1772008231,"startTime":"0","endTime":"0","summary":"科济药业-B北京时间02月25日，跌2.22%，卖空量成交7.05万股，较上一交易日减少80%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225163353a71d5a2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225163353a71d5a2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","02171","BK1587","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613718140","title":"科济药业-B(02171.HK)拟3月6日举行董事会会议以审批年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2613718140","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613718140?lang=zh_cn&edition=full","pubTime":"2026-02-24 19:17","pubTimestamp":1771931828,"startTime":"0","endTime":"0","summary":"格隆汇2月24日丨科济药业-B(02171.HK)公告，董事会兹通告谨定于2026年3月6日(星期五)举行董事会会议，以考虑及通过集团截至2025年12月31日止年度的全年业绩，以及处理其他事项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260224/32024300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","BK1585","BK1161","02171","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613229760","title":"每日卖空追踪 | 科济药业-B 02月20日卖空量成交26.45万股，卖空比例为11.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613229760","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613229760?lang=zh_cn&edition=full","pubTime":"2026-02-20 16:30","pubTimestamp":1771576227,"startTime":"0","endTime":"0","summary":"科济药业-B北京时间02月20日，涨3.65%，卖空量成交26.45万股，较上一交易日增加84.32%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220163341a70ccff5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220163341a70ccff5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","BK1587","BK1585","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613297601","title":"科济药业-B02月20日主力净流入261.6万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2613297601","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613297601?lang=zh_cn&edition=full","pubTime":"2026-02-20 16:16","pubTimestamp":1771575362,"startTime":"0","endTime":"0","summary":"02月20日, 科济药业-B股价涨3.65%，报收15.62元，成交金额3547.0万元，换手率0.40%，振幅7.90%，量比2.19。科济药业-B今日主力资金净流入261.6万元，上一交易日主力净流出0万元。该股近5个交易日上涨12.13%，主力资金累计净流入524.3万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入57.6万元，其中净流入天数为8日。该股主力净额占比0.03%，港股市场排名125/2717。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220162041a4b5dedc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220162041a4b5dedc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","BK1585","02171","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611101864","title":"科济药业-B盘中异动 大幅拉升5.42%报15.180港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611101864","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611101864?lang=zh_cn&edition=full","pubTime":"2026-02-16 09:47","pubTimestamp":1771206427,"startTime":"0","endTime":"0","summary":"2026年02月16日早盘09时47分，科济药业-B股票出现波动，股价急速拉升5.42%。截至发稿，该股报15.180港元/股，成交量22.45万股，换手率0.04%，振幅5.14%。资金方面，该股资金流入192.318万港元，流出72.7525万港元。科济药业-B股票所在的生物技术行业中，整体涨幅为0.13%。其相关个股中，中慧生物-B、北海康成-B、中生北控生物科技涨幅较大，振幅较大的相关个股有中慧生物-B、中生北控生物科技、北海康成-B，振幅分别为15.34%、14.43%、12.90%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260216094707a4a8fca7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260216094707a4a8fca7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1585","BK1161","02171","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105729756","title":"科济药业签署战略合作协议 扩建上海金山CAR-T商业化生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=1105729756","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105729756?lang=zh_cn&edition=full","pubTime":"2026-02-13 08:15","pubTimestamp":1770941713,"startTime":"0","endTime":"0","summary":"科济药业（股票代码：02171）近日与相关方达成战略合作，计划对其位于上海金山区的CAR-T细胞治疗商业化生产基地进行产能扩建。此次合作旨在提升CAR-T疗法的规模化生产能力，满足日益增长的市场需求。通过扩建生产基地，科济药业将进一步加强其在细胞治疗领域的商业化布局，为未来产品上市提供坚实的生产保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1585","BK1574","BK1587","BK1161","02171"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.carsgen.com","stockEarnings":[{"period":"1week","weight":0.0223},{"period":"1month","weight":0.216},{"period":"3month","weight":0.1498},{"period":"6month","weight":0.0774},{"period":"1year","weight":0.5435},{"period":"ytd","weight":0.266}],"compareEarnings":[{"period":"1week","weight":0.0217},{"period":"1month","weight":0.0077},{"period":"3month","weight":-0.0442},{"period":"6month","weight":-0.0096},{"period":"1year","weight":0.2269},{"period":"ytd","weight":0.0012}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"科济药业控股有限公司是一家主要从事探索、研发细胞疗法的投资控股公司。该公司的主营业务是开发嵌合抗原受体T细胞（CAR-T）细胞疗法，以满足临床需求，包括但不限于血液恶性肿瘤、实体瘤及自身免疫性疾病。该公司的主要产品包括赛恺泽（泽沃基奥仑赛注射液）、舒瑞基奥仑赛注射液、通用型CAR-T细胞产品。该公司在中国和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.07858},{"month":2,"riseRate":0.6,"avgChangeRate":0.230493},{"month":3,"riseRate":0.2,"avgChangeRate":-0.058535},{"month":4,"riseRate":0.4,"avgChangeRate":-0.055974},{"month":5,"riseRate":0.75,"avgChangeRate":0.085205},{"month":6,"riseRate":0.5,"avgChangeRate":0.033426},{"month":7,"riseRate":0.4,"avgChangeRate":-0.015336},{"month":8,"riseRate":0.6,"avgChangeRate":0.066197},{"month":9,"riseRate":0.4,"avgChangeRate":0.033481},{"month":10,"riseRate":0.6,"avgChangeRate":0.024843},{"month":11,"riseRate":0.6,"avgChangeRate":0.051023},{"month":12,"riseRate":0.4,"avgChangeRate":-0.058482}],"exchange":"SEHK","name":"科济药业-B","nameEN":"CARSGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科济药业-B,02171,科济药业-B股票,科济药业-B股票老虎,科济药业-B股票老虎国际,科济药业-B行情,科济药业-B股票行情,科济药业-B股价,科济药业-B股市,科济药业-B股票价格,科济药业-B股票交易,科济药业-B股票购买,科济药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}